全文获取类型
收费全文 | 87050篇 |
免费 | 7759篇 |
国内免费 | 3015篇 |
专业分类
耳鼻咽喉 | 359篇 |
儿科学 | 1788篇 |
妇产科学 | 773篇 |
基础医学 | 20364篇 |
口腔科学 | 958篇 |
临床医学 | 6573篇 |
内科学 | 19905篇 |
皮肤病学 | 1840篇 |
神经病学 | 4565篇 |
特种医学 | 3271篇 |
外国民族医学 | 11篇 |
外科学 | 6304篇 |
综合类 | 9606篇 |
现状与发展 | 16篇 |
预防医学 | 4464篇 |
眼科学 | 1165篇 |
药学 | 8380篇 |
14篇 | |
中国医学 | 2657篇 |
肿瘤学 | 4811篇 |
出版年
2023年 | 1086篇 |
2022年 | 1928篇 |
2021年 | 2695篇 |
2020年 | 2486篇 |
2019年 | 3408篇 |
2018年 | 3463篇 |
2017年 | 3140篇 |
2016年 | 3058篇 |
2015年 | 3397篇 |
2014年 | 5212篇 |
2013年 | 6019篇 |
2012年 | 4711篇 |
2011年 | 5349篇 |
2010年 | 4117篇 |
2009年 | 3914篇 |
2008年 | 3950篇 |
2007年 | 4063篇 |
2006年 | 3608篇 |
2005年 | 3128篇 |
2004年 | 2893篇 |
2003年 | 2638篇 |
2002年 | 2176篇 |
2001年 | 1983篇 |
2000年 | 1695篇 |
1999年 | 1513篇 |
1998年 | 1468篇 |
1997年 | 1438篇 |
1996年 | 1168篇 |
1995年 | 1182篇 |
1994年 | 1112篇 |
1993年 | 919篇 |
1992年 | 635篇 |
1991年 | 486篇 |
1990年 | 449篇 |
1989年 | 370篇 |
1988年 | 294篇 |
1987年 | 230篇 |
1986年 | 222篇 |
1985年 | 687篇 |
1984年 | 827篇 |
1983年 | 620篇 |
1982年 | 626篇 |
1981年 | 563篇 |
1980年 | 492篇 |
1979年 | 451篇 |
1978年 | 360篇 |
1977年 | 287篇 |
1976年 | 340篇 |
1975年 | 307篇 |
1974年 | 247篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Revista espa?ola de anestesiología y reanimación》2020,67(5):245-252
Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds.In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). Vitamin C, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitamin C in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves.Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal. 相似文献
4.
5.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
6.
7.
8.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献
9.
目的:探讨老年人桡骨远端C型骨折的手术治疗与非手术治疗的疗效差异,评价两种方法的优缺点。方法回顾性分析2009-12—2011-12收治的老年桡骨远端C型骨折68例,按照治疗方法分为A组(手术组)及B组(非手术组),统计分析两组患者的临床资料。结果 A组33例, B组35例,平均随访21.5个月。两组患者的年龄、骨折类型均无差异(P>0.05);术后影像学指标A组优于B组,骨折愈合时间B组优于A组,治疗成本A组大于B组(P<0.05);Cooney评分早期A组优于B组,1年后两组无差异,两组的并发症无差异(P>0.05)。结论老年人桡骨远端C型骨折手术治疗较非手术治疗可获得更好的复位及早期功能,但远期功能恢复无差异。 相似文献
10.
目的:观察PCR仪与测序仪在丙型肝炎病毒(HCV)基因型检测中的应用。方法:选择2018年1月~2018年12月收治的134例HCV感染患者为研究对象,给予患者PCR仪检测、测序仪检测。结果:测序仪检测134例均可分型,PCR仪检测130例患者可分型,4例未能分型。PCR检测结果:134例HCV感染患者中,1b型59例,2a型47例,3a型6例,3b型15例,6a型3例,4例为分出型别。基因测序结果:134例均可分型:1型59例,2a型40例,2i型7例,3a型6例,3b型15例,6a型3例,6n型4例。PCR仪检测法检测符合率97.0%。结论:PCR仪测序仪检测用于丙型肝炎病毒基因型检测,操作便捷,但其只能检测探针覆盖的型别,个别罕见型别不能分型。 相似文献